EPS for OncoSec Medical Incorporated (ONCS) Expected At $

Leading up to this report, we have seen a -4.04% return in the stock price over the last 30 days and a -9.25% return over the past 3 months.

ONCS's Beta value is 3.03. Similarly, the Value Composite Two (VC2) is calculated with the same ratios, but adds the Shareholder Yield.

OncoSec Medical Incorporated (NASDAQ:ONCS) is anticipated to reveal earnings on June, 7., RTT reports. A company with a value of 0 is thought to be an undervalued company, while a company with a value of 100 is considered an overvalued company. So, volatility evaluation is supposed to give some wisdom of how far the stock will fall if the market takes a dive and how high the stock will rise if the bull starts to climb. Real estate, healthcare and technology stocks posted the biggest percentage losses. Being ready for a pullback can help if investors already have some names in mind that they are looking to scoop up when they fall to a certain level. The Price Index 12m for OncoSec Medical Incorporated (NasdaqCM:ONCS) is 1.57426. (NASDAQ:AAL) recently had a high trading volume day. Institutional investors own 8.84% of the company's stock. A company that manages their assets well will have a higher return, while a company that manages their assets poorly will have a lower return. The MF Rank of OncoSec Medical Incorporated (NasdaqCM:ONCS) is 18598. This ranking uses four ratios. OncoSec Medical Incorporated price was kept to a minimum $1.57 in intra-day trade and has returned 5.23% this year alone. When looking at the ERP5 ranking, it is generally considered the lower the value, the better. Analysts at Wall Street see OncoSec Medical Incorporated's -41.67 % EPS growth compared to $-0.24 EPS for last quarter. The 6 month volatility is 72.979, and the 3 month is spotted at 69.1653. The stock is now showing positive return of 0.79% throughout last week and witnessed bearish return of -6.80% in one month period. Although past volatility action may help project future stock volatility, it may also be vastly different when taking into account other factors that may be driving price action during the measured time period. Some have challenged this idea, claiming that the data show little relation between beta and potential reward, or even that lower-beta stocks are both less risky and more profitable (contradicting CAPM).

OncoSec Medical traded up $0.11, reaching $1.71, during trading on Monday, according to MarketBeat. Market capitalization is simply the value that can get when multiply all the outstanding shares of a stock by the price of a single share.

The Price Index is a ratio that indicates the return of a share price over a past period.

Declining issues outnumbered advancing ones on the NYSE by a 1.87-to-1 ratio; on Nasdaq, a 1.14-to-1 ratio favoured decliners. Analysts forecast 36.36 % diference or $-0.14 from the $-0.22 EPS from 2017. The stock price closed last trading at $0.35.

At the time of writing, OncoSec Medical Incorporated (NasdaqCM:ONCS) has a Piotroski F-Score of 2. The F-Score may help discover companies with strengthening balance sheets.

When analyzing volume, there are guidelines that can be used to determine the strength or weakness of a move. The last close places the company's stock about $1.24 off its 52 week high of $2.95 and $0.83 above the 52 week low of $0.88.

OncoSec Medical Incorporated has an M-score Beneish of -999.

The M-Score, conceived by accounting professor Messod Beneish, is a model for detecting whether a company has manipulated their earnings numbers or not. The specifics of the variables and formula can be found in the Beneish paper "The Detection of Earnings Manipulation". The name now has a score of 50. This score is derived from the Gross Margin (Marx) stability and growth over the previous eight years. Value of 89. The Q.i.